Diffusion MRI measures of white matter microstructure distinguished people with corticobasal syndrome (CBS) from healthy controls more strongly than either regional brain volume or 18F-flortaucipir tau PET, according to a cross-sectional study posted as a preprint on medRxiv on 24 July 2026 by Yuqi Tian, Ryota Satoh, Val J. Lowe, Keith A. Josephs and Jennifer L. Whitwell of Mayo Clinic in Rochester, Minnesota. The work has not been certified by peer review. Ranked by area under the curve, mean diffusivity showed the strongest overall separation of the two groups, followed by the NODDI measure of intracellular volume fraction, then structural volume, then tau PET with a dominant global component removed, with unadjusted tau PET producing the smallest values. The authors describe it as the first direct comparison of these modalities in CBS.
The study enrolled 32 participants meeting research criteria for possible or probable CBS, recruited prospectively at Mayo Clinic between January 2018 and December 2025, alongside 35 age and sex matched participants with no cognitive, motor or behavioural complaints. Each underwent 3T diffusion MRI processed through diffusion tensor, free water and NODDI pipelines, volumetric MRI, and flortaucipir PET. People with biomarker evidence of Alzheimer's disease, defined as positivity on both a global amyloid PET measure and a temporal lobe tau PET measure, were excluded, so that the sample would more likely reflect an underlying 4-repeat tauopathy. Diffusion abnormalities were widespread and heaviest in sensorimotor and projection pathways; volume loss was most prominent in the precentral cortex, putamen, thalamus and pallidum. In targeted sensorimotor analyses, higher mean diffusivity tracked lower grey matter volume, while unadjusted tau uptake did not predict white matter change.
The finding bears on how trials in corticobasal degeneration and related 4R tauopathies choose what to measure. The authors themselves urge caution about the tau PET result, noting that autoradiography work, including a 2016 study led by Lowe, has shown flortaucipir binds strongly to Alzheimer-type paired helical filament tau but weakly or inconsistently in non-Alzheimer tauopathies, with off-target signal that complicates regional readings. On that reading, the comparison may say as much about the limits of a first-generation tracer as about the biology of the disease, and newer tau ligands were not tested here.
CBS is a clinical syndrome rather than a pathological diagnosis, and no participant in this study had autopsy confirmation of what was causing it. The cohort was single centre and modest in size, and every scan was a snapshot.